Torres, Tiago http://orcid.org/0000-0003-0404-0870
Puig, Luis
Vender, Ron
Lynde, Charles
Piaserico, Stefano
Carrascosa, Jose M.
Gisondi, Paolo
Daudén, Esteban
Conrad, Curdin
Mendes-Bastos, Pedro
Ferreira, Paulo
Leite, Luiz
Lu, Justin D.
Valerio, J.
Bruni, M.
Messina, F.
Nidegger, A.
Llamas-Velasco, M.
del Alcazar, E.
Mufti, A.
White, Kyra
Caldarola, G.
Teixeira, Laetitia
Romanelli, Paolo
Desai, K.
Gkalpakiotis, Spyridon
Romanelli, Marco
Yeung, Jensen
Nogueira, Miguel
Chiricozzi, Andrea
Article History
Accepted: 6 March 2021
First Online: 30 March 2021
Declarations
:
: None.
: T. Torres has received honoraria for acting as a consultant and/or as a speaker from AbbVie, Almirall, Amgen, Arena Pharmaceuticals, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Leo Pharma, MSD, Novartis, Pfizer, Samsung-Bioepis, Sandoz, and Sanofi. L. Puig has received honoraria for acting as a consultant and/or as a speaker from AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Celgene, Gebro, Janssen, Leo Pharma, Lilly, Merck-Serono, MSD, Novartis, Pfizer, Regeneron, Roche, and Sandoz. R. Vender has received grants/research support and acted as speaker/consultant from Abbvie, Amgen, Bausch-Health, Celgene, Centocor, Dermira, Dermavant, Galderma, GSK, Leo, Lilly, Takeda, Novartis, Merck, Mylan, Palladin, Pfizer, Regeneron, Sandoz, Sanofi, Sentrex, Sun, and UCB. C. Lynde has been a speaker, consultant and/or private investigator for AbbVie, Allergan, Amgen, Aralez, Arcutis, Bausch Health, Bayer, Boehringer Ingelheim, Celgene, Cipher, Dermavant, Eli Lilly, Galderma, Genentech, Glenmark, GSK, Innovaderm, Janssen, Kyowa, L’Oreal, LeoPharma, Merck, Medexus, Mylan, Novartis, Pediapharm, Pfizer, Procter and Gamble, Roche, Sandoz, Sanofi Adventis, Sanofi Genzyme, Stiefel, TEVA, and Valeant. S. Piaserico has been a consultant and/or speaker for Abbvie, Almirall, Amgen, Janssen, LEO Pharma, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Sandoz, and UCB. J.M. Carrascosa has participated as investigator and/or advisor and/or invited speaker for Abbvie, Janssen, Novartis, Lilly, Leo-Pharma, Almirall, Amgen, Sandoz, Mylan, and Pfizer. P. Gisondi has received honoraria for acting as a consultant and/or as a speaker from AbbVie, Almirall, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Leo Pharma, MSD, Novartis, Pfizer, Sandoz, Sanofi, and UCB. E. Daudén has the following conflict of interests: Advisory Board member, consultant, grants, research support, participation in clinical trials, honorarium for speaking, research support, with the following pharmaceutical companies: Abbvie/Abbott, Almirall, Amgen, Janssen-Cilag, Leo Pharma, Novartis, Pfizer, MSD-Schering-Plough, Celgene, Lilly, and UCB. C. Conrad has served as scientific adviser and/or clinical study investigator and/or paid speaker for AbbVie, Actelion, Amgen, BMS, Celgene, Galderma, Incyte, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Samsung, and UCB. P. Mendes-Bastos has received honoraria for acting as a consultant and/or as a speaker from AbbVie, Pfizer, Janssen, LEO Pharma, Novartis, Sanofi, Teva, Bayer, and L’Oreal. P. Ferreira has received honoraria for acting as a consultant and/or as a speaker from AbbVie, Janssen, LEO-Pharma, Eli-Lilly, Novartis, and Pfizer. L. Leite: none. J.D. Lu: none. J. Valerio: none. M. Bruni: none. F. Messina: none. A. Nidegger: none. M. Llamas-Velasco: none. E. del Alcazar has participated as SI and/or invited speaker for Abbvie, Janssen, Novartis, Lilly, Leo-Pharma, Almirall, Amgen, UCB, and Sanofi. A. Mufti: none. K. White: none. G. Caldarola: none. L. Teixeira: none. P. Romanelli: none. K. Desai: none. S. Gkalpakiotis has received honoraria for acting as a consultant and/or as a speaker from Abbvie, Amgen, Eli Lilly, Novartis, Leo Pharma, and Janssen-Cilag. M. Romanelli has been an advisory board member and consultant and has received fees and speaker’s honoraria or has participated in clinical trials for Abbvie, Abiogen, Almirall, Lilly, Mundipharma, Novartis, Leo Pharma, Smith & Nephew, Urgo Medical, Hartman, and Sanofi. J. Yeung has been a speaker, consultant, and investigator for AbbVie, Allergan, Amgen, Astellas, Boehringer Ingelheim, Celgene, Centocor, Coherus, Dermira, Eli Lilly, Forward, Galderma, GSK, Janssen, Leo, Medimmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Takeda, UCB, Valeant, and Xenon. M. Nogueira has received honoraria for acting as a speaker from Leo Pharma. A. Chiricozzi has served as advisory board member and consultant and has received fees and speaker's honoraria or has participated in clinical trials for AbbVie, Almirall, Biogen, Fresenius Kabi, Leo Pharma, Lilly, Janssen, Novartis, Sanofi Genzyme, and UCB Pharma.
: The present study was conducted in accordance with the Declaration of Helsinki initially published in 1964 on Ethical Principles for Medical Research Involving Human Subjects and after approval by the local ethical committees.
: Not applicable.
: Not applicable.
: Raw data are available on request from the authors.
: Not applicable.
: TT and AC contributed to the study concept and design. TT, LP, LT and AC conducted the statistical analyses on the data. All authors participated in data collection, interpreted the data, provided critical feedback on the manuscript, approved the final manuscript for submission, and were accountable for the accuracy and integrity of the article.